Content
10/06/2020
Agoura Hills, CA USA
A2 Biotherapeutics
completed $71.5 million Series B Round funding. Investors include
The Column Group, Vida Ventures, Samsara BioCapital, Nextech Invest, Casdin Capital, Euclidean Capital, UC Investments.
About
A2 Biotherapeutics' mission is to beat cancer via tumor-specific targeting by addressing targets gained or lost in cancer cells which unequivocally discriminate tumor from normal tissue. The company is focused on addressing the next frontier in cancer cell therapy, solid tumors. A2 Biotherapeutics leverages a powerful platform designed specifically for cell therapies that enables identification of rare binders derived from antibodies or T-cell receptors, precision binder engineering and optimization, and modular signaling construct designs.
Startup
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
